FMR LLC - 27 Jul 2021 Form 4 Insider Report for Caribou Biosciences, Inc. (CRBU)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
29 Jul 2021, 14:52:59 UTC
Prior SEC filing
22 Jul 2021
Next SEC filing
29 Jul 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Kevin M. Meagher, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson

Key filing fact

FMR LLC filed Form 4 for Caribou Biosciences, Inc. (CRBU) on 29 Jul 2021.

Key facts

  • This page summarizes FMR LLC's Form 4 filing for Caribou Biosciences, Inc. (CRBU).
  • 8 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 29 Jul 2021, 14:52.

Change

  • Previous filing in this sequence was filed on 22 Jul 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBU transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+770,510
Change %
Price
Shares after
770,510
Date
27 Jul 2021
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Footnotes
F1
CRBU transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+1,070,427
Change %
+139%
Price
Shares after
1,840,937
Date
27 Jul 2021
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Footnotes
F1
CRBU transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+17,572
Change %
Price
Shares after
17,572
Date
27 Jul 2021
Ownership
F-Prime Capital Partners Healthcare Advisors Fund IV LP
Footnotes
F1
CRBU transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+1,464,775
Change %
Price
Shares after
1,464,775
Date
27 Jul 2021
Ownership
Impresa Fund III Limited Partnership
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBU transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares
-423,823
Change %
-100%
Price
Shares after
0
Date
27 Jul 2021
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Underlying class
Common Stock
Underlying amount
770,510
Exercise price
Footnotes
F1
CRBU transaction Derivative

Series A-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-588,794
Change %
-100%
Price
Shares after
0
Date
27 Jul 2021
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Underlying class
Common Stock
Underlying amount
1,070,427
Exercise price
Footnotes
F1
CRBU transaction Derivative

Series A-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-9,666
Change %
-100%
Price
Shares after
0
Date
27 Jul 2021
Ownership
F-Prime Capital Partners Healthcare Advisors Fund IV LP
Underlying class
Common Stock
Underlying amount
17,572
Exercise price
Footnotes
F1
CRBU transaction Derivative

Series A-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-805,707
Change %
-100%
Price
Shares after
0
Date
27 Jul 2021
Ownership
Impresa Fund III Limited Partnership
Underlying class
Common Stock
Underlying amount
1,464,775
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

FMR LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.

SEC remarks

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Healthcare Advisors Fund IV LP (FPCPHA) is the general partner of F-Prime Capital Partners Healthcare Fund IV LP. FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .